Study wrapper · #889
Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs.
Bitar ER, Besir K, Cummins KC, et al. Journal of gastrointestinal surgery. 2026.
DOI: 10.1016/j.gassur.2026.102497PubMed: 42447648
Editor's note
This large TriNetX cohort compared semaglutide and tirzepatide users against bariatric surgery and other weight-loss drugs, finding therapeutic-dose use associated with lower colorectal and pancreatic cancer incidence and no increased cancer risk. Both tracked peptides are genuine subjects. As a retrospective, propensity-matched study it supports safety reassurance but cannot prove causation, and any-dose effects were not significant.
Plain-language abstract
In a large retrospective cohort of nondiabetic adults with obesity, therapeutic-dose semaglutide or tirzepatide use was associated with lower rates of colorectal and pancreatic cancer than bariatric surgery, with no signal of increased cancer risk.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026